Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

T0070907

HY-13202

(T-0070907; T 0070907)

T0070907

T0070907 Chemical Structure

T0070907 is a potent and selective PPARγ antagonist with IC50 of 1 nM; displays > 800-fold selectivity for PPARγ over PPARα and PPARδ.

Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
5 mg $50 In-stock
10 mg $60 In-stock
50 mg $216 In-stock
100 mg $412 In-stock
200 mg Get quote
500 mg Get quote
Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO €54 In-stock
5 mg €49 In-stock
10 mg €59 In-stock
50 mg €212 In-stock
100 mg €404 In-stock
200 mg Get quote
500 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: T0070907
Cat. No.: HY-13202

T0070907 Data Sheet

  • View current batch:

    Purity: 100.00%

  • Network Version

    DataSheet

    Pdf Version Network Version

    MSDS

    Pdf Version

    COA

    Pdf Version

    NMR

    Pdf Version

    LCMS

Customer View

Related Compound Libraries

Biological Activity of T0070907

T0070907 is a potent and selective PPARγ antagonist  with IC50 of 1 nM; displays > 800-fold selectivity for PPARγ over PPARα and PPARδ.
IC50 Value: 1 nM
Target: PPARγ
in vitro: T0070907 blocks agonist-induced recruitment of coactivator-derived peptides to PPARγ in a homogeneous time-resolved fluorescence-based assay and promotes recruitment of the transcriptional corepressor NCoR to PPARγ in both glutathione S-transferase pull-down assays and a PPARγ/retinoid X receptor (RXR) α-dependent gel shift assay. Studies with mutant receptors suggest that T0070907 modulates the interaction of PPARγ with these cofactor proteins by affecting the conformation of helix 12 of the PPARγ ligand-binding domain. Interestingly, whereas the T0070907-induced NCoR recruitment to PPARγ/RXRα heterodimer can be almost completely reversed by the simultaneous treatment with RXRα agonist LGD1069, T0070907 treatment has only modest effects on LGD1069-induced coactivator recruitment to the PPARγ/RXRα heterodimer. T0070907 treatment inhibits proliferation, invasion and migration but does not significantly affect apoptosis. Molecular inhibition using a dominant negative (Δ462) receptor yields similar results. T007 also mediates a dose-dependent decrease in phosphorylation of PPARγ, and its ability to bind to DNA, and may directly affect mitogen-activated protein kinase signaling.
in vivo: Lipopolysaccharide preconditioning significantly attenuates the development of renal dysfunction, hepatocellular injury, and circulatory failure as well as the increase in the plasma levels of interleukin-1 [beta] caused by severe endotoxemia. T0070907 can attenuate all of these beneficial effects afforded by preconditioning with lipopolysaccharide.
 

Protocol (Extracted from published papers and Only for reference)

More

Chemical Information

M.Wt 277.66 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C12H8ClN3O3
CAS No 313516-66-4
Solvent & Solubility

DMSO 26 mg/mL; Water <1.1 mg/mL

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 3.6015 mL 18.0076 mL 36.0153 mL
5 mM 0.7203 mL 3.6015 mL 7.2031 mL
10 mM 0.3602 mL 1.8008 mL 3.6015 mL

References on T0070907

Inhibitor Kit

Related PPAR Products

  • Aleglitazar

    Aleglitazar(R1439; RO-0728804) is a new dual PPAR-(alpha)/(gamma) agonist with IC50 of 2.8 nM/4.6 nM.

  • Balaglitazone

    Balaglitazone (DRF-2593; NN-2344) is a novel partial agonist of PPAR-(gamma).

  • Bezafibrate

    Bezafibrate(BM15075) is the first clinically tested dual and pan-PPAR co-agonism.

  • BMS-687453

    BMS-687453 is a potent and selective PPAR(alpha) agonist, with an EC50 of 10 nM for human PPAR(alpha) and 410-fold selectivity vs human PPAR(gamma) in PPAR-GAL4 transactivation assays.

  • CDDO-Im

    CDDO-Im(RTA-403) is a novel synthetic triterpenoid more potent than its parent compound CDDO both in vitro and in vivo; PPAR(gamma) agonist.

  • Clofibrate

    Clofibrate (Atromid-S), a fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia.

  • DG172 dihydrochloride

    DG172 dihydrochloride is a novel PPAR(beta)/(delta)-selective ligand showing high binding affinity (IC50 = 27 nM) and potent inverse agonistic properties.

  • Elafibranor

    Elafibranor (GFT505) is an agonist of the peroxisome proliferator-activated receptor(PPAR)-(alpha) and -(delta), induces resolution of nonalcoholic steatohepatitis without fibrosis worsening.

  • Fenofibrate

    Fenofibrate is PPAR(alpha) agonist with EC50 of 18 (mu)M and 30 (mu)M for mouse and human PPAR(alpha), respectively.

  • FH535

    FH535 is a compound that suppresses both Wnt/beta-catenin and peroxisome proliferator-activated receptor (PPAR) signaling.

MORE